MEDNAX, Inc. [NYSE:MD]: Analyst Rating and Earnings
Expert stock traders often make certain they pay attention what leading Wall Street analysts think regarding a potential stock purchase. As it relates to MEDNAX, Inc. [MD] currently, the latest ratings from Wall St. experts that can be seen publicly is related to the fiscal quarter that’s scheduled to end in December. On average, stock market experts give MD an Hold rating. Its stock price has been found in the range of 2.06 to 7.60. This is compared to its latest closing price of $34.35.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for MEDNAX, Inc. [MD] is sitting at 2.56. This is compared to 1 month ago, when its average rating was 2.69.
For the quarter ending in Dec-18 MEDNAX, Inc. [MD] generated $0.93 billion in sales. That’s 2.57% higher than the average estimate of $0.91 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.
Pay attention to the next-scheduled financial results for this company to be released, which is slated for Mon 29 Apr (In 76 Days).
Fundamental Analysis of MEDNAX, Inc. [MD]
Now let’s turn to look at profitability: with a current Operating Margin for MEDNAX, Inc. [MD] sitting at +12.22 and its Gross Margin at +24.08, this company’s Net Margin is now 9.50%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is 8.93, and its Return on Invested Capital has reached 6.50%. Its Return on Equity is 8.73, and its Return on Assets is 4.55. These metrics show a mixed bag, which means that this investment’s attractiveness can be quickly increased or decreased in the short term, depending on future updates MD financial performance.
Turning to investigate this organization’s capital structure, MEDNAX, Inc. [MD] has generated a Total Debt to Total Equity ratio of 63.94. Similarly, its Total Debt to Total Capital is 39.00, while its Total Debt to Total Assets stands at 33.27. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 63.94, and its Long-Term Debt to Total Capital is 39.00. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.
What about valuation? This company’s Enterprise Value to EBITDA is 9.07 and its Total Debt to EBITDA Value is 3.54. The Enterprise Value to Sales for this firm is now 1.39, and its Total Debt to Enterprise Value stands at 0.40.
Similarly, this company’s Receivables Turnover is 6.97 and its Total Asset Turnover is 0.62.
Let’s now turn our attention to trading performance: MEDNAX, Inc. [MD] has 92.55M shares outstanding, amounting to a total market cap of $3.18B. Its stock price has been found in the range of 31.68 to 63.04. At its current price, it has moved by -45.11% from its 52-week high, and it has moved 9.22% from its 52-week low.
This stock’s Beta value is currently 0.64, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 37.85. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is MEDNAX, Inc. [MD] a Reliable Buy?
Shares of MEDNAX, Inc. [MD], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.